Adrenergic action in breast cancer

Autores
Luthy, Isabel Alicia; Bruzzone, Ariana; Perez, Cecilia
Año de publicación
2012
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Breast cancer is the most frequent malignancy in women in the majority of western countries. Both acute and chronic stress cause the release of epinephrine and norepinephrine. These natural cateholamines bind to nine different adrenoceptors. Breast cancer epithelial cells express α2 and β2-adrenoceptors. Catecholamine binding to α2-adrenoceptors in cancer cells is associated with increased cell proliferation. On the contrary, catecholamine binding to β2-adrenoceptors result in diminished cell proliferation. Therefore, the relative concentration of these receptors in the tumor cell will enhance or diminish proliferation. Also in vivo, following stimulation with natural catecholamines, the tumor will experience enhanced or diminished growth depending on the relative concentration of α2 and β2-adrenoceptors. The administration of synthetic α2-adrenergic agonists enhances tumor growth whereas the administration of the α2-adrenergic antagonist rauwolscine diminishes tumor growth below control levels, behaving as an inverse agonist. The administration of β- adrenergic agonists could also be useful to lower tumor growth. The use of β-blockers in patients have been described by several groups as very promising specially in the case of the HER2 positive and triple negative tumors. Thus different therapeutic compounds targeting adrenergic receptors could become very important drugs for the treatment of selected cancer patients. Currently, adrenergic agonists/antagonists are used for the treatment of different diseases and have minimal side effects when compared with chemotherapy. The possibility of using them for treatment of breast cancer is an encouraging concept especially for the patients with resistance to the usual anti-cancer therapy.
Fil: Luthy, Isabel Alicia. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
Fil: Bruzzone, Ariana. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
Fil: Perez, Cecilia. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
Materia
ADRENOCEPTORS
BREAST CANCER
HUMAN
MAMMARY TUMOR
MOUSE
RAUWOLSCINE
YOHIMBINE
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/243700
Acceder
id CONICETDig_edc5545849ffb89e7c655f990d6a49eb
oai_identifier_str oai:ri.conicet.gov.ar:11336/243700
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Adrenergic action in breast cancerLuthy, Isabel AliciaBruzzone, ArianaPerez, CeciliaADRENOCEPTORSBREAST CANCERHUMANMAMMARY TUMORMOUSERAUWOLSCINEYOHIMBINEhttps://purl.org/becyt/ford/3.1https://purl.org/becyt/ford/3Breast cancer is the most frequent malignancy in women in the majority of western countries. Both acute and chronic stress cause the release of epinephrine and norepinephrine. These natural cateholamines bind to nine different adrenoceptors. Breast cancer epithelial cells express α2 and β2-adrenoceptors. Catecholamine binding to α2-adrenoceptors in cancer cells is associated with increased cell proliferation. On the contrary, catecholamine binding to β2-adrenoceptors result in diminished cell proliferation. Therefore, the relative concentration of these receptors in the tumor cell will enhance or diminish proliferation. Also in vivo, following stimulation with natural catecholamines, the tumor will experience enhanced or diminished growth depending on the relative concentration of α2 and β2-adrenoceptors. The administration of synthetic α2-adrenergic agonists enhances tumor growth whereas the administration of the α2-adrenergic antagonist rauwolscine diminishes tumor growth below control levels, behaving as an inverse agonist. The administration of β- adrenergic agonists could also be useful to lower tumor growth. The use of β-blockers in patients have been described by several groups as very promising specially in the case of the HER2 positive and triple negative tumors. Thus different therapeutic compounds targeting adrenergic receptors could become very important drugs for the treatment of selected cancer patients. Currently, adrenergic agonists/antagonists are used for the treatment of different diseases and have minimal side effects when compared with chemotherapy. The possibility of using them for treatment of breast cancer is an encouraging concept especially for the patients with resistance to the usual anti-cancer therapy.Fil: Luthy, Isabel Alicia. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; ArgentinaFil: Bruzzone, Ariana. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; ArgentinaFil: Perez, Cecilia. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; ArgentinaBentham Science Publishers2012-08info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/243700Luthy, Isabel Alicia; Bruzzone, Ariana; Perez, Cecilia; Adrenergic action in breast cancer; Bentham Science Publishers; Current Cancer Therapy Reviews; 8; 2; 8-2012; 90-991573-39471875-6301CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://www.benthamscience.com/article/42945info:eu-repo/semantics/altIdentifier/doi/10.2174/157339412800675397info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-03T10:01:41Zoai:ri.conicet.gov.ar:11336/243700instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-03 10:01:42.135CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Adrenergic action in breast cancer
title Adrenergic action in breast cancer
spellingShingle Adrenergic action in breast cancer
Luthy, Isabel Alicia
ADRENOCEPTORS
BREAST CANCER
HUMAN
MAMMARY TUMOR
MOUSE
RAUWOLSCINE
YOHIMBINE
title_short Adrenergic action in breast cancer
title_full Adrenergic action in breast cancer
title_fullStr Adrenergic action in breast cancer
title_full_unstemmed Adrenergic action in breast cancer
title_sort Adrenergic action in breast cancer
dc.creator.none.fl_str_mv Luthy, Isabel Alicia
Bruzzone, Ariana
Perez, Cecilia
author Luthy, Isabel Alicia
author_facet Luthy, Isabel Alicia
Bruzzone, Ariana
Perez, Cecilia
author_role author
author2 Bruzzone, Ariana
Perez, Cecilia
author2_role author
author
dc.subject.none.fl_str_mv ADRENOCEPTORS
BREAST CANCER
HUMAN
MAMMARY TUMOR
MOUSE
RAUWOLSCINE
YOHIMBINE
topic ADRENOCEPTORS
BREAST CANCER
HUMAN
MAMMARY TUMOR
MOUSE
RAUWOLSCINE
YOHIMBINE
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.1
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Breast cancer is the most frequent malignancy in women in the majority of western countries. Both acute and chronic stress cause the release of epinephrine and norepinephrine. These natural cateholamines bind to nine different adrenoceptors. Breast cancer epithelial cells express α2 and β2-adrenoceptors. Catecholamine binding to α2-adrenoceptors in cancer cells is associated with increased cell proliferation. On the contrary, catecholamine binding to β2-adrenoceptors result in diminished cell proliferation. Therefore, the relative concentration of these receptors in the tumor cell will enhance or diminish proliferation. Also in vivo, following stimulation with natural catecholamines, the tumor will experience enhanced or diminished growth depending on the relative concentration of α2 and β2-adrenoceptors. The administration of synthetic α2-adrenergic agonists enhances tumor growth whereas the administration of the α2-adrenergic antagonist rauwolscine diminishes tumor growth below control levels, behaving as an inverse agonist. The administration of β- adrenergic agonists could also be useful to lower tumor growth. The use of β-blockers in patients have been described by several groups as very promising specially in the case of the HER2 positive and triple negative tumors. Thus different therapeutic compounds targeting adrenergic receptors could become very important drugs for the treatment of selected cancer patients. Currently, adrenergic agonists/antagonists are used for the treatment of different diseases and have minimal side effects when compared with chemotherapy. The possibility of using them for treatment of breast cancer is an encouraging concept especially for the patients with resistance to the usual anti-cancer therapy.
Fil: Luthy, Isabel Alicia. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
Fil: Bruzzone, Ariana. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
Fil: Perez, Cecilia. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
description Breast cancer is the most frequent malignancy in women in the majority of western countries. Both acute and chronic stress cause the release of epinephrine and norepinephrine. These natural cateholamines bind to nine different adrenoceptors. Breast cancer epithelial cells express α2 and β2-adrenoceptors. Catecholamine binding to α2-adrenoceptors in cancer cells is associated with increased cell proliferation. On the contrary, catecholamine binding to β2-adrenoceptors result in diminished cell proliferation. Therefore, the relative concentration of these receptors in the tumor cell will enhance or diminish proliferation. Also in vivo, following stimulation with natural catecholamines, the tumor will experience enhanced or diminished growth depending on the relative concentration of α2 and β2-adrenoceptors. The administration of synthetic α2-adrenergic agonists enhances tumor growth whereas the administration of the α2-adrenergic antagonist rauwolscine diminishes tumor growth below control levels, behaving as an inverse agonist. The administration of β- adrenergic agonists could also be useful to lower tumor growth. The use of β-blockers in patients have been described by several groups as very promising specially in the case of the HER2 positive and triple negative tumors. Thus different therapeutic compounds targeting adrenergic receptors could become very important drugs for the treatment of selected cancer patients. Currently, adrenergic agonists/antagonists are used for the treatment of different diseases and have minimal side effects when compared with chemotherapy. The possibility of using them for treatment of breast cancer is an encouraging concept especially for the patients with resistance to the usual anti-cancer therapy.
publishDate 2012
dc.date.none.fl_str_mv 2012-08
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/243700
Luthy, Isabel Alicia; Bruzzone, Ariana; Perez, Cecilia; Adrenergic action in breast cancer; Bentham Science Publishers; Current Cancer Therapy Reviews; 8; 2; 8-2012; 90-99
1573-3947
1875-6301
CONICET Digital
CONICET
url http://hdl.handle.net/11336/243700
identifier_str_mv Luthy, Isabel Alicia; Bruzzone, Ariana; Perez, Cecilia; Adrenergic action in breast cancer; Bentham Science Publishers; Current Cancer Therapy Reviews; 8; 2; 8-2012; 90-99
1573-3947
1875-6301
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/https://www.benthamscience.com/article/42945
info:eu-repo/semantics/altIdentifier/doi/10.2174/157339412800675397
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
application/pdf
application/pdf
dc.publisher.none.fl_str_mv Bentham Science Publishers
publisher.none.fl_str_mv Bentham Science Publishers
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1842269712089612288
score 13.13397

Publicaciones similares